KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Inventory Average (2016 - 2025)

Historic Inventory Average for Halozyme Therapeutics (HALO) over the last 15 years, with Q4 2025 value amounting to $181.1 million.

  • Halozyme Therapeutics' Inventory Average rose 3256.79% to $181.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $181.1 million, marking a year-over-year increase of 3256.79%. This contributed to the annual value of $159.2 million for FY2025, which is 1813.77% up from last year.
  • As of Q4 2025, Halozyme Therapeutics' Inventory Average stood at $181.1 million, which was up 3256.79% from $183.7 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Inventory Average high stood at $183.7 million for Q3 2025, and its period low was $50.8 million during Q1 2022.
  • In the last 5 years, Halozyme Therapeutics' Inventory Average had a median value of $124.1 million in 2023 and averaged $116.2 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Inventory Average crashed by 1462.84% in 2022, and later skyrocketed by 10423.53% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Inventory Average stood at $54.9 million in 2021, then skyrocketed by 85.1% to $101.7 million in 2022, then rose by 26.12% to $128.3 million in 2023, then rose by 6.53% to $136.6 million in 2024, then soared by 32.57% to $181.1 million in 2025.
  • Its last three reported values are $181.1 million in Q4 2025, $183.7 million for Q3 2025, and $173.2 million during Q2 2025.